	US 12,458,618 B2
	Compounds and methods for the detection of TRPV-6 cancers and drug delivery
John M. Stewart, Sackville (CA)
Assigned to Soricimed Biopharma Inc., Moncton (CA)
Filed by Soricimed Biopharma Inc., Moncton (CA)
Filed on Jul. 15, 2021, as Appl. No. 17/376,670.
Application 17/376,670 is a division of application No. 16/046,786, filed on Jul. 26, 2018, granted, now 11,090,396.
Application 16/046,786 is a continuation of application No. 14/579,157, filed on Dec. 22, 2014, granted, now 10,064,964, issued on Sep. 4, 2018.
Application 14/579,157 is a continuation of application No. 12/824,935, filed on Jun. 28, 2010, abandoned.
Claims priority of provisional application 61/244,634, filed on Sep. 22, 2009.
Claims priority of provisional application 61/220,833, filed on Jun. 26, 2009.
Prior Publication US 2022/0175977 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 33/24 (2019.01); A61K 33/242 (2019.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/64 (2017.01); A61K 49/00 (2006.01); A61K 49/14 (2006.01); A61K 49/16 (2006.01); A61K 49/18 (2006.01); A61K 51/10 (2006.01); B82Y 5/00 (2011.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01)

CPC A61K 31/337 (2013.01) [A61K 33/24 (2013.01); A61K 39/0005 (2013.01); A61K 45/06 (2013.01); A61K 47/64 (2017.08); A61K 49/0032 (2013.01); A61K 49/0056 (2013.01); A61K 49/0058 (2013.01); A61K 49/14 (2013.01); A61K 49/16 (2013.01); A61K 49/1866 (2013.01); A61K 51/1093 (2013.01); B82Y 5/00 (2013.01); C07K 16/28 (2013.01); G01N 33/57415 (2013.01); G01N 33/57434 (2013.01); G01N 33/57449 (2013.01); G01N 33/57492 (2013.01); G01N 33/6872 (2013.01); A61K 33/242 (2019.01); G01N 2333/705 (2013.01)]

8 Claims

1. A method for the treatment of cancer by delivering a biomolecule to a cell expressing Transient Receptor Potential Vanilloid 6 (TRPV6), comprising contacting the cell in vivo with a compound comprising a TRPV6-binding peptide conjugated to the biomolecule, wherein the biomolecule is an anti-cancer agent, and wherein the TRPV6-binding peptide:

a) comprises from 9 to 27 contiguous C-terminal amino acids of SEQ ID NO:1;

b) has an amino acid sequence with at least 90% identity to HPSKVDLPR (SEQ ID NO: 3);

c) has an amino acid sequence with at least 90% identity to KEFLHPSKVDLPR (SEQ ID NO: 4); or

d) has an amino acid sequence with at least 90% identity to

	(SEQ ID NO: 1)
	EGKLSSNDTEGGLCKEFLHPSKVDLPR.